Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple ...

NEW YORK – Akeso Biopharma on Wednesday said it dosed the first patient with PD-L1-positive advanced head and neck cancer in a Phase III trial, comparing the activity of its PD-1/VEGF bispecific ...

Summit Therapeutics PLC ( (SMMT) ) has realeased its Q3 earnings. Here is a breakdown of the information Summit Therapeutics PLC presented to ...

Quarterly Cash Burn: Below $35 million for operating activities. Summit Therapeutics Inc (NASDAQ:SMMT) has made significant ...

The latest update is out from Summit Therapeutics ( (SMMT) ).